Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v clinical trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

This study is testing a new medicine, Onpattro, for a heart condition called ATTR amyloidosis. It compares the medicine to a dummy treatment to see if it improves walking ability and overall heart health in adults.